Patients with invasive lobular and ductal carcinoma or pleomorphic lobular carcinoma might increase pathologic complete response rate and lower mastectomy rates compared to classical lobular type

2019 ◽  
Vol 120 (3) ◽  
pp. 565-565
Author(s):  
Kadri Altundag
Keyword(s):  
Response Rate ◽  
Ductal Carcinoma ◽  
Complete Response Rate ◽  
Lobular Carcinoma ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Pleomorphic Lobular Carcinoma ◽  
Pathologic Complete Response Rate

scholarly journals Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Oncotarget ◽  
2018 ◽  
Vol 9 (41) ◽  
pp. 26406-26416 ◽  
Author(s):  
Angela Santonja ◽  
Alfonso Sánchez-Muñoz ◽  
Ana Lluch ◽  
Maria Rosario Chica-Parrado ◽  
Joan Albanell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Response Rate ◽  
Complete Response Rate ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Cancer Subtypes ◽  
Pathologic Complete Response Rate

Modeling precision genomic-based radiation dose response in rectal cancer

2020 ◽  
Vol 16 (30) ◽  
pp. 2411-2420
Author(s):  
Zhigang Yuan ◽  
Marissa Frazer ◽  
Kamran A Ahmed ◽  
Syeda Mahrukh Hussnain Naqvi ◽  
Michael J Schell ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Radiation Dose ◽  
Dose Response ◽  
Response Rate ◽  
Complete Response Rate ◽  
Prospective Trial ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Bimodal Distribution ◽  
Pathologic Complete Response Rate

Aim: Genomic-based risk stratification to personalize radiation dose in rectal cancer. Patients & methods: We modeled genomic-based radiation dose response using the previously validated radiosensitivity index (RSI) and the clinically actionable genomic-adjusted radiation dose. Results: RSI of rectal cancer ranged from 0.19 to 0.81 in a bimodal distribution. A pathologic complete response rate of 21% was achieved in tumors with an RSI <0.31 at a minimal genomic-adjusted radiation dose of 29.76 when modeling RxRSI to the commonly prescribed physical dose of 50 Gy. RxRSI-based dose escalation to 55 Gy in tumors with an RSI of 0.31–0.34 could increase pathologic complete response by 10%. Conclusion: This study provides a theoretical platform for development of an RxRSI-based prospective trial in rectal cancer.

Sign in / Sign up

Export Citation Format

Share Document